M&A: Year of the megadeal


M&A: Year of the megadeal

Peshkova / Shutterstock.com

LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.

Deal-making experienced a lull over the winter period last year, but this was the calm before the storm. A January 3 announcement from US pharmaceutical company Bristol-Myers Squibb (BMS) reignited a stream of mergers and acquisitions (M&A) activity in the life sciences space.

BMS revealed it would purchase Celgene, a drug manufacturer focusing on new cancer and inflammation treatments, for $74 billion.

It marked the start of a busy 2019, and was the first of seven megadeals (deals valued at $5 billion plus) announced in the first half of this year, according to PwC.

M&A, life sciences, drug manufacturer, Celgene, megadeals, oncology, pharmaceuticals, AI, machine learning, innovative therapies, R&D, CAR-T, Brexit, tech